Predictive Oncology Inc. POAI Archives - Page 13 of 19

WednesdayApr 22, 2020 11:15 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Distinctive Business Model in Exclusive Interview

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its director and CEO Dr. Carl Schwartz was featured in an exclusive interview with NetworkNewsWire (“NNW”). In the interview, Dr. Schwartz discussed Predictive Oncology’s distinctive business model, as well as significant changes management is making to position the company for the future. “Predictive’s major asset is its Helomics subsidiary and its proprietary database of over 150,000 cancer tumors covering over 137 types of cancers, with over 30,000 tumors related to ovarian cancer, which is sort of our specialty.…

TuesdayApr 21, 2020 12:58 pm

Predictive Oncology Inc. (NASDAQ: POAI) Releases FY Financials, Notes Key Partnerships, CancerQuest 2020 Milestones Achieved

Q4 highlights include $15 million equity line, CancerQuest 2020 initiative POAI revenues for FY 2019 total $1.4 million, primarily driven through sale of proprietary STREAMWAY units Predictive Oncology will continue to be pioneer in fields of biomarker discovery, precision therapies Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying its cutting-edge technology to cancer research, released its financial report for fiscal year 2019, ending December 31, 2019. The report also identified fourth-quarter highlights for the company (http://ibn.fm/CRxo2). Noting that 2019 “was not without its challenges for the entire healthcare technology industry,” POAI CFO Bob Myers observed that Predictive Oncology “continued to…

FridayApr 17, 2020 12:16 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Securities Purchase Agreement to Raise $3.5 Million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock (http://ibn.fm/9l1rL). An article discussing the company reads, “The company explained that it has entered into a securities purchase agreement with certain accredited investors to raise $3.5 million through the issuance of up to 1,650,165 shares of common stock (or common stock equivalents) and accompanying warrants to purchase an aggregate of up to 3,300,330 shares of common stock at $2.121 per share of common stock…

ThursdayApr 09, 2020 12:29 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Continues Progress Toward AI-Driven Predictive Model of Ovarian Cancer

POAI’s Helomics division progresses toward critical milestone in CancerQuest2020 initiative Predictive models immensely valuable to pharmaceutical industry, improving drug evaluation without incurring high laboratory costs POAI is bringing precision medicine to the treatment of cancer for patients of today and tomorrow Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer. This achievement will be a key milestone for the company’s CancerQuest2020 initiative (http://ibn.fm/mENY6). CancerQuest2020 is focused on building an AI-driven…

TuesdayApr 07, 2020 3:07 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Vaccine, Drug-Development Platform Targeting Coronaviruses, Acute Respiratory Syndromes

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced the launch of a new AI vaccine and drug development platform targeting coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS). An article discussing the company reads, “Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to create…

WednesdayApr 01, 2020 10:59 am

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Full-Year 2019

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today released financial results for its full year ended December 31, 2019, as well as select corporate highlights. Among the highlights, the company reported its securing of a $15.0 million equity line with Oasis Capital, LLC, as well as its new subsidiary, Helomics, reaching milestone sequencing tumor cases in partnership with UPMC Magee. “2019 was not without its challenges for the entire healthcare technology industry, yet we continued to execute on our business model, making a synergistic acquisition and shoring up…

TuesdayMar 31, 2020 12:03 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Helomics’ Continued Progress Toward Developing AI-Driven Predictive Model of Ovarian Cancer

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020). Per the update, CancerQuest2020 (CCQ2020) is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome. Predictive models embody the knowledge from these profiles, creating a “computational expert” or a “virtual patient” that can be queried. “Despite some headwinds imposed by the current COVID-19 pandemic, the Helomics team has been working diligently to…

ThursdayMar 26, 2020 12:41 pm

Predictive Oncology Inc. (NASDAQ: POAI) Enters into Securities Purchase Agreement to Raise $3.5 Million

POAI announces securities purchase agreement with accredited investors to purchase shares of common stock Company to use net proceeds from purchase agreement for general corporate purposes Agreement expected to raise $3.5 million through issuance of up to 1,650,165 shares of common stock or common stock equivalents Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock; the company plans to use the net proceeds from the purchase agreement for general corporate purposes. POAI, a company that focuses on providing predictive models of tumor drug…

MondayMar 23, 2020 12:27 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Secures $3.5 Million in Private Placement

Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced its March 19, 2020, closing on its previously announced private offering of common stock and warrants resulting in gross proceeds of $3,498,612 to the Company. Per the offering, the Company sold and issued 1,650,166 shares of common stock (or common stock equivalents) and issued Series A warrants to acquire 1,650,166 shares of Common Stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of…

ThursdayMar 19, 2020 12:24 pm

AI Accelerates Vaccine Development; Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Platform to Battle Coronaviruses, Acute Respiratory Syndromes

Artificial Intelligence at the forefront of scientific discovery, proving importance in complex diseases Predictive Oncology launches new AI platform in fight against new pathogens Artificial intelligence likely to help find COVID-19 vaccines and therapeutics With the global onslaught of COVID-19, scientists are turning to the speed and power of artificial intelligence to find solutions. The complexity of this lethal contagion demands a rapid response, and only advanced computer systems can parse through massive amounts of data swiftly enough to help stem the pandemic. Artificial intelligence can sort and sift data quickly, spot patterns and make predictions – which can then…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI